GLP-1, short for glucagon-like peptide-1, is an endogenous peptide hormone and incretin, meaning a gut-derived signal that helps coordinate insulin secretion after eating, and human research has studied native GLP-1 physiology as well as GLP-1 receptor agonist medicines in glycemic control, weight regulation, gastrointestinal function, cardiovascular outcomes, kidney outcomes, and emerging addiction-related research (Review).
GLP-1 is not a typical vitamin, mineral, herb, or over-the-counter supplement ingredient; it is a hormone made in the body and a biological target for prescription drug development (Review). Native GLP-1 human studies often use meal tests, blood-level measurements, or intravenous infusions, while many large modern trials study GLP-1 receptor agonists, which are medicines designed to activate the GLP-1 receptor more durably than native GLP-1 (Research) (Research). The strongest human evidence is in Diabetes and Glycemic Control and Obesity and Weight Regulation, while areas such as Substance Use and Recovery remain early and hypothesis-generating (Review) (Review).
Ingredient Identity
- Official name(s): Glucagon-like peptide-1; GLP-1 (Review).
- Synonyms: GLP-1, incretin hormone GLP-1, proglucagon-derived peptide (Review).
- Classification: Endogenous peptide hormone and incretin; a peptide is a small chain of amino acids, and an incretin is a gut hormone that helps link food intake to insulin secretion (Review).
- CAS number: Not summarized in the approved human-evidence source set.
- Endogenous vs exogenous: Native GLP-1 is produced in the body, while GLP-1 receptor agonists are externally administered medicines that activate the same receptor system more persistently than native GLP-1 (Review) (FDA).
Ingredient Snapshot
- Classification: GLP-1 is a gut-derived peptide hormone in the incretin family, meaning it helps the body connect nutrient intake with insulin secretion (Review).
- Endogenous vs exogenous status: Native GLP-1 is endogenous, while GLP-1 receptor agonists such as semaglutide and liraglutide are exogenous prescription medicines that act on the GLP-1 receptor (FDA) (EMA).
- Primary human research domains: The major human research areas include Diabetes and Glycemic Control, Obesity and Weight Regulation, Digestive and Gastrointestinal Health, Cardiovascular Health, Kidney Health, Liver Health, and emerging Substance Use and Recovery research (Review) (Review).
- Common study formats: Human studies include meal-test physiology studies, intravenous infusion studies, subcutaneous native GLP-1 studies, randomized GLP-1 receptor agonist trials, and systematic reviews of clinical outcomes (Research) (Research).
- Pharmacokinetic characterization status: Native GLP-1 is rapidly broken down by the enzyme DPP-4, which is one reason many clinical medicines are designed as longer-acting GLP-1 receptor agonists rather than native GLP-1 itself (Review).
- Regulatory context in the U.S. and EU: In the U.S. and EU, GLP-1 receptor agonists are regulated as prescription medicines rather than ordinary dietary supplements (FDA) (EMA).
- Evidence maturity: Human evidence is mature for some prescription GLP-1 receptor agonist uses in glycemic control and weight regulation, but native GLP-1 itself is mainly studied in controlled physiology settings rather than consumer-style ingredient trials (Review) (Research).
Introduction
GLP-1 is made from the larger proglucagon molecule and is released mainly by specialized intestinal cells called L cells after nutrient exposure (Review). In plain terms, GLP-1 is one of the body’s meal-response signals, helping the pancreas, stomach, brain, and liver coordinate what happens after food enters the digestive system (Review).
People often look up GLP-1 because GLP-1 receptor agonists are widely studied medicines for Diabetes and Glycemic Control and Obesity and Weight Regulation, while native GLP-1 research helps explain the body’s normal meal-response biology (Review) (Review). Human studies have also examined gastric emptying, appetite ratings, cardiovascular outcomes, kidney outcomes, liver-health markers, and early addiction-related outcomes (Research) (Research).
This article is informational only, describes GLP-1 as a biochemical substance studied in human research, and does not provide medical or dosing advice.
Quick Summary
- GLP-1 is an endogenous peptide hormone, not a conventional supplement ingredient, and it is best understood as a biological signal involved in post-meal insulin, glucagon, stomach-emptying, and appetite responses (Review).
- Human evidence is strongest for GLP-1 receptor agonist medicines in Diabetes and Glycemic Control and Obesity and Weight Regulation, where large randomized trials and meta-analyses have reported clinically meaningful outcome changes (Review) (Research).
- Native GLP-1 itself has been studied through blood measurements and controlled infusions rather than consumer-style oral supplement dosing (Research) (Research).
- GLP-1 receptor agonists are designed to last longer than native GLP-1, which is rapidly degraded by DPP-4, an enzyme that cuts and inactivates GLP-1 in the circulation (Review).
- Digestive and Gastrointestinal Health research shows that GLP-1 can slow gastric emptying, meaning it can slow the rate at which food leaves the stomach (Research).
- Kidney Health and Cardiovascular Health evidence is strongest for prescription GLP-1 receptor agonist trials and outcome meta-analyses, not for over-the-counter GLP-1 supplementation (Research) (Review).
- Substance Use and Recovery research is early, with small randomized human studies and reviews describing the area as preliminary rather than established (Research) (Review).
Human Research Findings by Condition
Diabetes and Glycemic Control
Human research in Diabetes and Glycemic Control includes native GLP-1 infusion studies, GLP-1 secretion studies, and large randomized trials of GLP-1 receptor agonists (Research) (Review). The evidence is strongest for prescription GLP-1 receptor agonists, while native GLP-1 physiology studies show how the hormone affects insulin, glucagon, and glucose in controlled settings (Research).
Key human study
Dose studied: Native GLP-1 infusion at 1 pmol/kg/min, which is approximately 14 micrograms per hour for a 154-lb adult when expressed as a research infusion estimate.
Population: Adults with type 2 diabetes.
Duration: 4 hours.
Researchers infused native GLP-1 into people with type 2 diabetes and observed lower fasting plasma glucose with increased insulin secretion during the study period (Research). This was a controlled physiology study, not a consumer supplement trial, and the dose was delivered as an intravenous infusion rather than as a capsule, food, or liquid serving (Research).
Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Limited
Study source: (Research)
Additional human study
Dose studied: Semaglutide 0.5 mg and 1.0 mg once weekly.
Population: Adults with type 2 diabetes.
Duration: 30 weeks.
SUSTAIN 1 studied once-weekly semaglutide, a GLP-1 receptor agonist, and reported improved HbA1c and body weight compared with placebo in adults with type 2 diabetes (Research). HbA1c is a blood test that reflects average blood sugar over roughly the prior 2–3 months, so it is commonly used in diabetes trials (Research).
Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Strong
Study source: (Research)
Obesity and Weight Regulation
Human research in Obesity and Weight Regulation is dominated by randomized trials and meta-analyses of GLP-1 receptor agonists rather than native GLP-1 itself (Research) (Review). Appetite and energy-intake studies also show that GLP-1 signaling can affect hunger and food intake in controlled human settings (Research).
Key human study
Dose studied: Semaglutide 2.4 mg once weekly.
Population: Adults with obesity or overweight without diabetes.
Duration: 68 weeks.
STEP 1 randomized adults with obesity or overweight to semaglutide or placebo alongside lifestyle intervention and reported substantially greater mean weight loss with semaglutide (Research). This study evaluated a prescription GLP-1 receptor agonist and should not be interpreted as evidence for oral GLP-1 supplements or non-prescription products (Research).
Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Strong
Study source: (Research)
Additional human study
Dose studied: Liraglutide 3.0 mg/day.
Population: Adults with obesity or overweight without type 2 diabetes.
Duration: 56 weeks.
A randomized trial of liraglutide, another GLP-1 receptor agonist, reported greater body-weight reduction with liraglutide than with placebo in adults without type 2 diabetes (Research). The study provides evidence for a prescription injectable medicine, not for native GLP-1 as a dietary ingredient (Research).
Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Strong
Study source: (Research)
Digestive and Gastrointestinal Health
Human studies in Digestive and Gastrointestinal Health show that GLP-1 can slow gastric emptying, meaning food leaves the stomach more slowly after GLP-1 exposure (Research). This effect is relevant to post-meal glucose patterns and medication absorption, but it also explains why gastrointestinal effects are closely monitored in GLP-1 receptor agonist safety research (Research) (Review).
Key human study
Dose studied: Native GLP-1 infusion at 0.3 and 0.9 pmol/kg/min, approximately 4 and 12 micrograms per hour for a 154-lb adult as research-infusion estimates.
Population: Healthy men.
Duration: Short post-meal experimental study.
Researchers found that both lower and higher intravenous GLP-1 infusion rates slowed solid and liquid gastric emptying in healthy subjects (Research). Because this was an intravenous research infusion, the findings cannot be converted into a serving size in milliliters unless the concentration of a specific solution is known (Research).
Result: Human studies observed short-term physiological effects
Evidence strength: Moderate
Study source: (Research)
Additional human study
Dose studied: Intravenous truncated GLP-1 exposure in a controlled human study.
Population: Healthy volunteers.
Duration: Acute experimental study.
A human study reported that truncated GLP-1 inhibited gastric emptying and pancreatic enzyme secretion in healthy volunteers (Research). Pancreatic enzymes are digestive proteins released by the pancreas to help break down food, so this study supports GLP-1’s role as a digestive signal rather than only a blood-sugar hormone (Research).
Result: Human studies observed short-term physiological effects
Evidence strength: Limited
Study source: (Research)
Endocrine Health
Endocrine Health refers to hormone systems, and GLP-1 is studied as a hormone that interacts with insulin, glucagon, and nutrient signals after meals (Review). Human evidence supports GLP-1 as part of the incretin effect, which is the stronger insulin response seen after oral nutrients compared with glucose delivered directly into the bloodstream (Research).
Key human study
Dose studied: Meal-related endogenous GLP-1 and GIP signaling.
Population: Healthy subjects.
Duration: Acute meal and glucose-clamp study.
A human study reported that GLP-1 and GIP contributed nearly equally to the incretin effect after a meal in healthy subjects (Research). GIP is another incretin hormone, and this study helps explain why incretin biology includes more than GLP-1 alone (Research).
Result: Human studies observed short-term physiological effects
Evidence strength: Moderate
Study source: (Research)
Additional human study
Dose studied: Endogenous GLP-1 receptor activity blocked during a mixed meal.
Population: Healthy adults.
Duration: Acute post-meal study.
A human study using GLP-1 receptor antagonism found that blocking GLP-1 signaling after a mixed meal altered post-meal glucagon and glucose regulation (Research). A receptor antagonist is a compound that blocks a receptor, so this design helps show what native GLP-1 normally contributes during meal metabolism (Research).
Result: Human studies observed short-term physiological effects
Evidence strength: Moderate
Study source: (Research)
Cardiovascular Health
Cardiovascular Health evidence differs sharply between native GLP-1 and GLP-1 receptor agonists (Research) (Review). Small native GLP-1 infusion studies have explored short-term heart-related physiology, while larger GLP-1 receptor agonist trials and meta-analyses provide stronger outcome-level evidence in populations with type 2 diabetes and cardiometabolic risk (Review).
Key human study
Dose studied: Native GLP-1 infusion at 0.7 pmol/kg/min, approximately 10 micrograms per hour for a 154-lb adult as a research-infusion estimate.
Population: Non-diabetic participants with compensated ischemic heart failure.
Duration: 48 hours.
A randomized crossover study reported metabolic effects from GLP-1 infusion but did not show major cardiovascular effects in compensated ischemic heart failure (Research). Ischemic heart failure means the heart’s pumping ability is impaired after reduced blood supply, often related to coronary artery disease (Research).
Result: Human clinical study reported no clear effect
Evidence strength: Limited
Study source: (Research)
Additional human study
Dose studied: GLP-1 infusion after reperfused acute myocardial infarction.
Population: Patients with acute myocardial infarction and left ventricular dysfunction.
Duration: Short clinical intervention period.
A clinical study examined GLP-1 infusion after reperfused acute myocardial infarction, a heart attack treated by restoring blood flow, in people with impaired left-ventricular function (Research). The study supports cardiovascular research interest, but its small clinical-study design requires cautious interpretation (Research).
Result: Human clinical study reported a modest improvement
Evidence strength: Emerging
Study source: (Research)
Kidney Health
Kidney Health evidence is most developed for GLP-1 receptor agonists studied in people with type 2 diabetes and chronic kidney disease (Research). Reviews and meta-analyses also evaluate kidney outcomes, but evidence outside diabetes-related kidney disease remains less mature (Review).
Key human study
Dose studied: Semaglutide 1.0 mg once weekly.
Population: Adults with type 2 diabetes and chronic kidney disease.
Duration: Median follow-up of 3.4 years.
FLOW randomized adults with type 2 diabetes and chronic kidney disease to semaglutide or placebo and reported reduced clinically important kidney outcomes and cardiovascular death (Research). Chronic kidney disease means the kidneys have reduced function or signs of kidney damage over time, and the trial studied a prescription GLP-1 receptor agonist rather than native GLP-1 exposure (Research).
Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Strong
Study source: (Research)
Additional human study
Dose studied: Multiple GLP-1 receptor agonist regimens across randomized trials.
Population: Trial populations with diabetes and kidney-risk outcomes.
Duration: Varied by included trial.
A cardiovascular and kidney outcomes meta-analysis found that GLP-1 receptor agonists reduced major cardiovascular events and kidney composite outcomes in populations with type 2 diabetes (Review). A composite outcome combines several clinically important events into one endpoint, which can improve statistical power but may combine outcomes of different patient importance (Review).
Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Strong
Study source: (Review)
Liver Health
Liver Health evidence for GLP-1 receptor agonists has focused on NAFLD and NASH, which are forms of fatty liver disease not primarily caused by alcohol (Review). The evidence is promising but mixed because studies vary in drug, dose, duration, liver-fat measurement method, diabetes status, and whether liver biopsy outcomes were included (Review).
Key human study
Dose studied: Multiple GLP-1 receptor agonist regimens across randomized trials.
Population: Adults with NAFLD or NASH in randomized trials.
Duration: Varied by included trial.
An updated meta-analysis evaluated GLP-1 receptor agonists for NAFLD and NASH outcomes and supported including Liver Health as a human research area (Review). NAFLD means nonalcoholic fatty liver disease, and NASH refers to a more inflammatory form called nonalcoholic steatohepatitis (Review).
Result: Human clinical studies reported mixed findings
Evidence strength: Moderate
Study source: (Review)
Substance Use and Recovery
Substance Use and Recovery research on GLP-1 receptor agonists is early and should be treated as exploratory (Review). Human studies are much smaller than the diabetes and obesity trial programs, and current evidence does not establish GLP-1 receptor agonists as standard addiction treatment (Research).
Key human study
Dose studied: Low-dose once-weekly semaglutide.
Population: Adults with alcohol use disorder.
Duration: Phase 2 randomized trial.
A phase 2 randomized trial reported that low-dose semaglutide reduced craving and some drinking outcomes in adults with alcohol use disorder (Research). Phase 2 means the study is still an early clinical stage and is generally used to estimate signals, tolerability, and study design needs rather than to establish definitive clinical use (Research).
Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Emerging
Study source: (Research)
Additional human study
Dose studied: Multiple GLP-1 receptor agonist study designs across substance-use research.
Population: Human participants in substance-use-disorder studies.
Duration: Varied by included study.
A systematic review and meta-analysis concluded that randomized human evidence for GLP-1 receptor agonists in substance use disorders remains limited and hypothesis-generating (Review). Hypothesis-generating means the evidence is useful for designing future trials but is not strong enough to support firm clinical conclusions (Review).
Result: Human evidence remains limited or inconclusive
Evidence strength: Emerging
Study source: (Review)
Dosage & Study Snapshot (Research Context)
Human GLP-1 research uses several measurement systems that do not translate cleanly into ordinary product units like teaspoons, capsules, or milliliters (Research) (Research). Blood concentrations such as pmol/L or pM describe how much GLP-1 is present in blood, while infusion rates such as pmol/kg/min describe how much GLP-1 is delivered per kilogram of body weight per minute (Research). For a rough plain-English translation, 1 pmol/L of native GLP-1 is approximately 3.3 pg/mL, so 15–20 pmol/L is about 50–66 pg/mL, or 0.05–0.07 ng/mL, but that describes blood concentration rather than a dose someone takes (Review). A milliliter is a volume measure, so studies cannot be converted to mL unless the concentration of a specific solution in mg/mL is provided.
0.4–1.4 pM endogenous basal GLP-1:
This is the lowest human exposure band in the cited evidence, and it refers to very small blood concentrations of naturally circulating GLP-1 before nutrient stimulation (Research). Because pM and pmol/L are effectively the same concentration scale, 0.4–1.4 pM is roughly 1.3–4.6 pg/mL, or 0.001–0.005 ng/mL, using native GLP-1 mass-equivalent estimates. This is not a dose in mg and not a volume in mL; it is a measured blood level. The study context was nutrient-response physiology in healthy volunteers, not supplementation or prescription-drug treatment (Research).
Result: Observational association
Evidence strength: Observational
Notes / limitations: This band describes endogenous blood concentration, not an amount administered.
10–12 pM postprandial endogenous GLP-1:
After nutrient exposure, endogenous GLP-1 rose into the 10–12 pM range in a human nutrient-response study (Research). In common mass-concentration terms, this is roughly 33–40 pg/mL, or 0.033–0.040 ng/mL, which is still far below milligram-scale amounts. Postprandial means “after a meal,” and the study measured the body’s own hormone response rather than giving GLP-1 as a product. This helps distinguish natural circulating hormone levels from pharmacological GLP-1 receptor agonist doses used in drug trials (Research).
Result: Observational association
Evidence strength: Observational
Notes / limitations: This exposure reflects meal-stimulated blood levels and does not define an oral GLP-1 dose.
15–20 pmol/L fasting and about 30 pmol/L post-meal GLP-1:
A review of GLP-1 measurement reported fasting levels around 15–20 pmol/L and post-meal peaks around 30 pmol/L in healthy volunteers (Review). Expressed in more familiar laboratory units, 15–20 pmol/L is roughly 50–66 pg/mL, or 0.05–0.07 ng/mL, while 30 pmol/L is roughly 99 pg/mL, or 0.10 ng/mL. These are blood concentration values, not a serving size, injection dose, or liquid volume. They help explain why GLP-1 physiology is usually described with lab units rather than consumer dosing units (Review).
Result: Observational association
Evidence strength: Observational
Notes / limitations: Different assays may measure total GLP-1, intact GLP-1, or related peptide forms differently.
0.3–0.9 pmol/kg/min intravenous native GLP-1:
Human gastric-emptying studies infused native GLP-1 intravenously at 0.3 and 0.9 pmol/kg/min (Research). For a 154-lb adult, those rates are approximately 4 and 12 micrograms per hour, or 0.004 and 0.012 mg per hour, as research-infusion estimates. The study reported slower gastric emptying and changes in post-meal glucose and insulin responses in healthy men (Research). These values cannot be converted into mL without knowing the concentration of the infused solution in mg/mL.
Result: Preliminary signal
Evidence strength: Moderate
Notes / limitations: Intravenous infusion bypasses digestion and is not comparable to an oral supplement format.
0.7–1.2 pmol/kg/min intravenous native GLP-1:
Native GLP-1 has been infused at 0.7 pmol/kg/min in compensated ischemic heart failure research and at 1.0–1.2 pmol/kg/min in glycemic-control physiology studies (Research) (Research). For a 154-lb adult, this approximate range is about 10–17 micrograms per hour, or 0.010–0.017 mg per hour. The type 2 diabetes study reported reduced fasting plasma glucose with increased insulin secretion, while the heart-failure study reported metabolic effects without clear major cardiovascular effects (Research) (Research). This dose band is useful for physiology interpretation, not for self-directed dosing.
Result: Mixed findings
Evidence strength: Limited
Notes / limitations: Findings differ by population and outcome, and the route was controlled infusion.
1.5–4.5 pmol/kg/min subcutaneous recombinant GLP-1:
A subcutaneous recombinant GLP-1 study used infusion rates of 1.5, 2.5, 3.5, and 4.5 pmol/kg/min in adults with type 2 diabetes (Research). For a 154-lb adult, this range is approximately 21–62 micrograms per hour, or 0.021–0.062 mg per hour, as a continuous infusion estimate. The study reported lower fasting serum glucose, but later route-comparison work found that subcutaneous native GLP-1 was much less bioavailable than intravenous GLP-1 (Research) (Research). Bioavailability means the fraction of an administered substance that reaches circulation in active form.
Result: Modest improvement
Evidence strength: Limited
Notes / limitations: Subcutaneous native GLP-1 delivery is formulation- and route-sensitive.
0.5–1.0 mg once-weekly semaglutide:
Semaglutide 0.5 mg and 1.0 mg once weekly were studied in adults with type 2 diabetes in SUSTAIN 1 (Research). These are ordinary mass-dose units in milligrams because semaglutide is a formulated prescription GLP-1 receptor agonist, not native GLP-1 blood concentration. The trial reported improved HbA1c and body weight compared with placebo over 30 weeks (Research). This dose band is not interchangeable with native GLP-1 pmol/L blood levels because semaglutide is engineered for longer action.
Result: Statistically significant improvement
Evidence strength: Strong
Notes / limitations: This evidence applies to a prescription GLP-1 receptor agonist studied under clinical-trial conditions.
0.6–1.8 mg/day liraglutide:
Liraglutide 0.6, 1.2, and 1.8 mg/day was studied with metformin in adults with type 2 diabetes (Research). The study reported improved glycemic control and body-weight reduction compared with placebo, with comparator context against glimepiride (Research). These are milligram-per-day prescription-drug doses, not endogenous GLP-1 concentrations. The evidence supports interpretation of a GLP-1 receptor agonist trial, not native GLP-1 supplementation.
Result: Statistically significant improvement
Evidence strength: Strong
Notes / limitations: The study included background metformin, so the results reflect the studied clinical context.
2.4 mg once-weekly semaglutide and 3.0 mg/day liraglutide:
Higher-dose GLP-1 receptor agonist obesity trials studied semaglutide 2.4 mg once weekly and liraglutide 3.0 mg/day (Research) (Research). These trials reported greater weight loss versus placebo in adults with obesity or overweight, with semaglutide studied over 68 weeks and liraglutide over 56 weeks (Research) (Research). The milligram amounts are medication doses and cannot be compared directly with picogram-per-milliliter native GLP-1 blood levels. The studies are highly relevant to prescription GLP-1 receptor agonist evidence, but not to food-derived or supplement-style GLP-1 exposure.
Result: Statistically significant improvement
Evidence strength: Strong
Notes / limitations: These were prescription-drug trials with clinical eligibility criteria, monitoring, and defined protocols.
Key Takeaways from Human Research
- Native GLP-1 is mainly studied as a short-lived hormone signal, while longer-acting GLP-1 receptor agonists make up much of the large modern clinical-trial evidence (Review) (Research).
- Diabetes and Glycemic Control has strong evidence for GLP-1 receptor agonists and mechanistic support from native GLP-1 infusion studies (Research) (Review).
- Obesity and Weight Regulation evidence is strong for several GLP-1 receptor agonist trials, especially semaglutide and liraglutide, but these data do not establish over-the-counter GLP-1 dosing (Research) (Research).
- Digestive and Gastrointestinal Health findings support GLP-1’s role in slowing gastric emptying, which is relevant to both glucose responses and gastrointestinal tolerability (Research) (Review).
- Kidney Health evidence has strengthened through large GLP-1 receptor agonist outcome trials in type 2 diabetes and chronic kidney disease (Research).
- Substance Use and Recovery remains emerging because the available human evidence is much smaller and less definitive than the diabetes and obesity evidence base (Research) (Review).
Origin & Natural Occurrence
GLP-1 is produced from proglucagon and released primarily by intestinal L cells in response to nutrients, hormones, and nerve-related signals (Review). L cells are specialized hormone-producing cells in the intestinal lining, and they help convert information about incoming food into signals that affect the pancreas, stomach, and brain (Review).
GLP-1 is not best described as a nutrient naturally present in meaningful amounts in common foods; instead, foods stimulate the body’s own GLP-1 release after eating (Review). Human nutrient-response research has measured fasting and post-meal GLP-1 concentrations, showing that endogenous levels can rise after nutrient ingestion (Research).
Manufactured GLP-1-related products in clinical research include native GLP-1 infusions, recombinant GLP-1, and GLP-1 receptor agonists such as semaglutide and liraglutide (Research) (Research). GLP-1 receptor agonists are not simply “more GLP-1”; they are engineered molecules that activate the GLP-1 receptor and are designed to last longer than native GLP-1 (Review).
How It Behaves in the Body
In simple terms, GLP-1 helps the body respond to food by signaling the pancreas, stomach, brain, and other tissues after nutrients enter the gut (Review). It can support insulin secretion when glucose is present, reduce glucagon in some settings, slow stomach emptying, and contribute to fullness signals (Review).
The word “receptor” means a cellular docking site that receives a signal, and GLP-1 acts through the GLP-1 receptor (FDA). GLP-1 receptor agonists are molecules that activate this docking site, and prescription examples are designed to produce longer-lasting receptor activation than native GLP-1 (FDA).
Native GLP-1 is rapidly degraded by DPP-4, an enzyme that cuts GLP-1 and reduces its active signaling life (Review). This rapid breakdown is one reason human physiology studies often use controlled infusions and why many medicines are designed as DPP-4-resistant or longer-acting receptor agonists (Review).
Well-established human biology includes GLP-1’s involvement in post-meal insulin secretion, glucagon regulation, gastric emptying, and appetite signaling (Review) (Research). Less established areas include whether GLP-1 receptor signaling can be translated into durable outcomes in Substance Use and Recovery or other emerging research domains (Review).
Absorption & Delivery Formats
Oral immediate-release: Native GLP-1 is a peptide, and peptide hormones are generally difficult to deliver orally because digestive processes and enzymatic degradation can limit intact absorption (Review). The cited human evidence for native GLP-1 relies mainly on blood measurements and injections or infusions rather than ordinary immediate-release oral dosing (Research).
Oral extended-release: The cited native GLP-1 studies do not establish an oral extended-release native GLP-1 format. Oral semaglutide exists as a prescription semaglutide product in FDA labeling resources, but that is a formulated GLP-1 receptor agonist medicine rather than native GLP-1 as a dietary ingredient (FDA).
Sublingual: Sublingual means held under the tongue for absorption through the mouth lining. The cited human evidence does not establish sublingual native GLP-1 as a validated clinical or supplement delivery format.
Transdermal: Transdermal means delivered through the skin. The cited human evidence does not establish transdermal native GLP-1 delivery as a validated GLP-1 research format.
Injectable / IV: Native GLP-1 human physiology studies commonly use intravenous infusion, and some recombinant GLP-1 studies have used subcutaneous delivery (Research) (Research). Prescription GLP-1 receptor agonist studies commonly use subcutaneous milligram dosing, including once-weekly semaglutide and once-daily liraglutide trial regimens (Research) (Research).
Quick Facts at a Glance
Onset reported: Native GLP-1 infusion studies can show short-term physiological effects during the infusion period, including glucose, insulin, glucagon, gastric-emptying, and appetite-related effects (Research) (Research). Meal-stimulated endogenous GLP-1 can rise after nutrient exposure, but that describes the body’s own hormone response rather than a product onset (Research).
Time to peak (Tmax): Tmax means “time to maximum concentration” in blood. For endogenous GLP-1, meal and nutrient studies measure post-meal rises rather than a conventional pill-dose Tmax (Research). For native GLP-1 infusion studies, the delivery method controls exposure, so Tmax is not directly comparable to oral supplement or capsule pharmacokinetics (Research).
Half-life (t½): Half-life means how long it takes for the amount of a substance in blood to fall by half. Native GLP-1 is rapidly degraded by DPP-4, which helps explain why longer-acting GLP-1 receptor agonists were developed (Review).
Typical duration: Native GLP-1 physiology studies often examine acute effects over hours, while GLP-1 receptor agonist clinical trials may run for months or years depending on the outcome (Research) (Research). This difference matters because a short infusion study and a long prescription-drug outcome trial answer different scientific questions (Research) (Research).
Absorption routes studied: Human native GLP-1 research includes intravenous and subcutaneous administration, and a route-comparison study found subcutaneous native GLP-1 to be much less bioavailable than intravenous GLP-1 (Research). Bioavailability means how much active substance reaches the bloodstream after administration.
Formulation differences: Native GLP-1, recombinant GLP-1, semaglutide, and liraglutide are not interchangeable formulations. Semaglutide and liraglutide are GLP-1 receptor agonist medicines studied at milligram doses, while native GLP-1 infusion studies use pmol/kg/min infusion rates (Research) (Research).
Variability drivers: GLP-1 levels and effects can vary by meal stimulus, assay type, route of delivery, body weight, diabetes status, and formulation (Review) (Research). Assay type matters because different laboratory tests may measure intact GLP-1, total GLP-1, or related peptide forms differently (Review).
Tolerance / adaptation: The cited human evidence does not establish a classic “tolerance” pattern for native GLP-1 as a supplement-like ingredient. Long GLP-1 receptor agonist trials show continued study over many weeks or years, but those data concern prescription receptor agonists rather than native GLP-1 tolerance (Research) (Research).
Evidence strength snapshot: Evidence is strong for several prescription GLP-1 receptor agonist outcomes in Diabetes and Glycemic Control and Obesity and Weight Regulation, moderate to strong for some cardiovascular and kidney outcomes in studied populations, and emerging for Substance Use and Recovery (Review) (Review) (Review). Evidence for native GLP-1 as an ordinary consumer ingredient is limited because the cited human studies are physiology and infusion studies rather than supplement trials (Research) (Research).
Safety, Interactions & Regulation
GLP-1 receptor agonist safety evidence includes randomized trials, meta-analyses, drug labeling, and regulatory safety reviews (Review) (FDA). Gastrointestinal adverse events are a major safety category in GLP-1 receptor agonist research, and a systematic review/meta-analysis of placebo-controlled randomized trials reported increased risk of some gastrointestinal outcomes (Review).
Pancreatitis and pancreatic cancer have been evaluated in randomized-trial meta-analysis, but individual trials may not be designed or powered primarily for rare safety outcomes (Review). A 2026 systematic review/meta-analysis reported that GLP-1 receptor agonists probably have little or no effect on risk for several obesity-related cancers within randomized placebo-controlled trial data, while noting limitations such as follow-up duration and cancer-outcome ascertainment (Review).
FDA requested removal of suicidal behavior and ideation warning language from certain GLP-1 receptor agonist labels after its review found no increased risk (FDA). EMA’s PRAC also concluded that available evidence did not support a causal association between GLP-1 receptor agonists and suicidal or self-injurious thoughts and actions (EMA).
Interaction categories include overlap with other GLP-1 receptor agonists or semaglutide-containing products, which FDA labeling identifies as a coadministration concern for Wegovy (FDA). Interaction interpretation can also involve gastric emptying because GLP-1 can slow stomach emptying, which is relevant when considering timing and absorption of orally administered substances (Research).
In the U.S., FDA has warned about unapproved GLP-1 drugs used for weight loss, including compounded semaglutide and tirzepatide products, and has emphasized concerns about dosing outside FDA-approved labeling (FDA). FDA labeling resources identify semaglutide products as prescription GLP-1 receptor agonist products rather than dietary supplements (FDA).
In the EU, EMA states that GLP-1 receptor agonists including Ozempic, Saxenda, Trulicity, Victoza, and Wegovy are authorized medicines for diabetes and/or weight-management indications depending on the product (EMA). EMA’s Wegovy and Ozempic product pages identify semaglutide as a GLP-1 receptor agonist within EU medicine authorization context (EMA) (EMA).
Evidence Overview
The overall human evidence for GLP-1 is strongest where GLP-1 receptor agonists have been tested in large randomized trials and systematic reviews, especially Diabetes and Glycemic Control and Obesity and Weight Regulation (Review) (Review). Native GLP-1 itself has strong physiological relevance but a much smaller controlled-infusion evidence base, so it should not be interpreted as having the same evidence profile as semaglutide, liraglutide, or other receptor agonist medicines (Research) (Research). Confidence is not higher across all GLP-1 topics because study designs differ widely by molecule, dose, route, duration, population, and endpoint (Research) (Research).
Diabetes and Glycemic Control evidence includes mechanistic native GLP-1 infusion studies and larger prescription-drug randomized trials (Research) (Research). Obesity and Weight Regulation evidence is supported by large semaglutide and liraglutide trials and by broader meta-analysis of GLP-1 receptor agonists in adults with overweight or obesity (Research) (Research) (Review).
Digestive and Gastrointestinal Health evidence is mechanistically strong for gastric emptying because human studies directly measured slowed gastric emptying during GLP-1 infusion (Research). Safety interpretation is more complex because gastrointestinal effects can be part of GLP-1 biology while also contributing to adverse-event patterns in GLP-1 receptor agonist trials (Review).
Cardiovascular Health and Kidney Health evidence has become more clinically developed through GLP-1 receptor agonist outcome trials and meta-analyses in cardiometabolic populations (Review) (Research). However, small native GLP-1 cardiovascular infusion studies should be viewed as mechanistic or exploratory rather than definitive outcome evidence (Research).
Liver Health evidence is supported by randomized-trial meta-analysis in NAFLD and NASH but remains heterogeneous because liver outcomes can be measured by imaging, enzymes, weight-related metabolic changes, or biopsy findings (Review). Substance Use and Recovery evidence is preliminary because the human evidence includes early-stage randomized work and synthesis papers that call for larger, more definitive studies (Research) (Review).
Evidence Confidence Classification
Moderate overall is the best classification for GLP-1 as an encyclopedia ingredient topic because the evidence is strong for several prescription GLP-1 receptor agonist outcomes but more limited for native GLP-1 as a standalone biochemical ingredient or supplement-style exposure (Review) (Research). The evidence base includes large randomized trials, systematic reviews, meta-analyses, physiology studies, and regulatory reviews, but these sources do not all study the same molecule or delivery format (Research) (Review). Confidence is strongest for Diabetes and Glycemic Control and Obesity and Weight Regulation, while it is emerging for Substance Use and Recovery and more context-dependent for Liver Health, Cardiovascular Health, and Kidney Health (Review) (Review).
Similar Ingredients & Comparators
Similar supplement-style or physiology-related ingredients and signals:
- GIP, another incretin hormone studied alongside GLP-1 (Research).
- Glucagon, a pancreatic hormone that GLP-1 can influence in some study settings (Research).
- Insulin, the hormone most closely linked to GLP-1’s post-meal glycemic effects (Review).
- DPP-4, the enzyme system that rapidly degrades native GLP-1 (Review).
- Proglucagon, the precursor molecule from which GLP-1 is produced (Review).
- Peptide YY, another gut-derived satiety-related peptide not directly reviewed in the cited GLP-1 source set.
- Amylin, another metabolic peptide hormone not directly reviewed in the cited GLP-1 source set.
Medical / pharma comparator categories:
- GLP-1 receptor agonists.
- Dual incretin agonists.
- DPP-4 inhibitors.
- Insulin therapies.
- Metformin-containing diabetes regimens.
- Sulfonylurea comparator regimens.
- Anti-obesity pharmacotherapy categories.
- Cardiometabolic outcome-trial drug categories.
Combination Context
GLP-1 + GIP:
GLP-1 and GIP were studied together because both are incretin hormones that help explain the insulin response to oral nutrients (Research). A human study reported that GLP-1 and GIP contributed nearly equally to the incretin effect of a meal in healthy subjects, while another study in hyperglycemic type 2 diabetes found that adding GIP did not potentiate GLP-1’s antidiabetic effect (Research) (Research).
GLP-1 receptor agonist + metformin context:
Liraglutide was studied with metformin in adults with type 2 diabetes because metformin is a common background therapy in diabetes trials (Research). This is a medicine-combination context rather than an ingredient-plus-ingredient supplement context, and the trial’s findings should be interpreted within that clinical design (Research).
GLP-1 receptor agonist + lifestyle intervention context:
Semaglutide obesity trials commonly included lifestyle intervention as part of the study design, meaning the medication effect was evaluated within a structured clinical protocol rather than as an isolated consumer ingredient exposure (Research). Lifestyle intervention is not an ingredient, but it is important context because weight-regulation trials often include diet and activity counseling in both active and placebo groups (Research).
FAQ
What is GLP-1?
GLP-1 is glucagon-like peptide-1, an endogenous peptide hormone released mainly from intestinal L cells after nutrient exposure (Review). A peptide is a small chain of amino acids, and a hormone is a chemical messenger that helps one part of the body signal another part (Review). GLP-1 is also called an incretin because it contributes to the insulin response after oral nutrient intake (Review).
What does human research study GLP-1 for?
Human research studies GLP-1 in Diabetes and Glycemic Control, Obesity and Weight Regulation, Digestive and Gastrointestinal Health, Cardiovascular Health, Kidney Health, Liver Health, and emerging Substance Use and Recovery contexts (Review) (Review). Native GLP-1 studies often examine short-term physiology such as insulin, glucagon, gastric emptying, and appetite (Research) (Research). GLP-1 receptor agonist studies often examine clinical endpoints over weeks, months, or years (Research) (Research).
What are the best-supported uses?
The best-supported human evidence is for prescription GLP-1 receptor agonists in Diabetes and Glycemic Control and Obesity and Weight Regulation (Review) (Review). Large randomized trials have reported improved HbA1c and body weight with semaglutide in type 2 diabetes and substantial weight loss with semaglutide in obesity or overweight (Research) (Research). These findings apply to studied prescription medicines and should not be generalized to unapproved GLP-1 products or supplement-style claims (FDA).
Where is evidence mixed or limited?
Evidence is more limited for native GLP-1 as a standalone consumer ingredient because human studies usually use infusions, injections, or physiology measurements rather than ordinary oral product dosing (Research) (Research). Liver Health evidence is mixed across NAFLD and NASH outcomes because studies vary in design, duration, drug, and endpoint (Review). Substance Use and Recovery evidence remains emerging and hypothesis-generating rather than established (Review).
How quickly does GLP-1 act?
Native GLP-1 can show short-term physiological effects during controlled human infusion studies, including effects on fasting glucose and gastric emptying (Research) (Research). Endogenous GLP-1 can rise after nutrient ingestion, but that is a natural post-meal hormone response rather than the onset of a product (Research). Prescription GLP-1 receptor agonists have different timing because they are engineered formulations studied at milligram doses over clinical-trial periods (Research) (Research).
What affects absorption and variability?
Route of delivery affects GLP-1 exposure because subcutaneous native GLP-1 can be much less bioavailable than intravenous native GLP-1 (Research). Assay type also affects interpretation because total GLP-1, intact GLP-1, and related peptide forms can produce different measured values (Review). Population factors such as diabetes status and meal stimulus can also influence measured GLP-1 responses (Review).
Is tolerance reported?
The cited human evidence does not establish a clear tolerance pattern for native GLP-1 as a supplement-style ingredient. Long-duration GLP-1 receptor agonist trials show continued study over 56–68 weeks or longer, but those are prescription-drug trials rather than native GLP-1 tolerance studies (Research) (Research). Tolerance should therefore not be assumed from the cited GLP-1 physiology evidence.
Why do studies disagree?
GLP-1 studies can appear to disagree because they may study native GLP-1, recombinant GLP-1, semaglutide, liraglutide, or broader GLP-1 receptor agonist classes (Research) (Research). They also differ in route, dose unit, treatment duration, population, and endpoint, which can change the interpretation of the findings (Research) (Research). A short infusion study measuring gastric emptying does not answer the same question as a 68-week obesity trial or a multi-year kidney outcome trial (Research) (Research) (Research).
What ingredients is GLP-1 commonly combined with and why?
The clearest ingredient-like physiology combination in the cited evidence is GLP-1 with GIP, because both are incretin hormones involved in the insulin response to oral nutrients (Research). GLP-1 receptor agonist trials also include medicine or lifestyle contexts, such as liraglutide with metformin or semaglutide with lifestyle intervention, but those are not ordinary supplement combinations (Research) (Research). The evidence does not support inventing supplement stacks for GLP-1.
What foods naturally contain GLP-1?
GLP-1 is not best understood as a food ingredient that people consume in meaningful natural amounts. Foods and nutrients stimulate the body’s own GLP-1 release after eating, which is why GLP-1 is studied as a post-meal gut hormone (Review). Human nutrient-response studies have measured changes in circulating GLP-1 after nutrient ingestion rather than measuring GLP-1 as a nutrient present in foods (Research).
How is GLP-1 regulated?
In the U.S., FDA regulates GLP-1 receptor agonist products such as semaglutide-containing medicines as prescription drugs rather than dietary supplements (FDA). FDA has also warned about unapproved GLP-1 drugs used for weight loss, including some compounded products and dosing concerns (FDA). In the EU, EMA describes GLP-1 receptor agonists as authorized medicines for diabetes and/or weight management depending on the specific product (EMA).
Resources
- The physiology of glucagon-like peptide-1 — PubMed — https://pubmed.ncbi.nlm.nih.gov/17928588/
- The incretin hormone GLP-1 and mechanisms underlying its secretion — PubMed — https://pubmed.ncbi.nlm.nih.gov/27287542/
- DPP-4 biology and GLP-1 degradation — PubMed — https://pubmed.ncbi.nlm.nih.gov/30828317/
- Native GLP-1 infusion in type 2 diabetes — PubMed — https://pubmed.ncbi.nlm.nih.gov/9827848/
- Semaglutide in obesity, STEP 1 — PubMed — https://pubmed.ncbi.nlm.nih.gov/33567185/
- Liraglutide in obesity — PubMed — https://pubmed.ncbi.nlm.nih.gov/26132939/
- FLOW kidney outcomes trial — PubMed — https://pubmed.ncbi.nlm.nih.gov/38785209/
- GLP-1 receptor agonists and cardiovascular/kidney outcomes meta-analysis — PubMed — https://pubmed.ncbi.nlm.nih.gov/34425083/
- FDA concerns about unapproved GLP-1 drugs used for weight loss — FDA — https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- EMA EU actions on GLP-1 receptor agonist shortages and authorization context — EMA — https://www.ema.europa.eu/en/news/eu-actions-tackle-shortages-glp-1-receptor-agonists